THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Lower sales of Tysabri predicted

Analysts alter targets after illnesses reported

By Todd Wallack
Globe Staff / August 6, 2008

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Financial analysts are predicting the number of patients using Tysabri will fall far below Biogen Idec Inc.'s forecast, following the Cambridge biotech company's disclosure last week that two more patients using the multiple sclerosis drug contracted a potentially fatal brain disease. (Full article: 317 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass